Evaluating anticancer drug therapies for gynecologic and breast cancers
Observational Study Evaluating the Efficacy and Tolerability of Anticancer Drug Therapies Adopted for the Treatment of Gynecologic and Breast Cancers in Clinical Practice Compared with the Results of Registration Studies
This study is testing different cancer drug treatments to see how well they work and how well patients with breast and gynecologic cancers can tolerate them.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna Academic / other |
| Locations | 1 site (Bologna) |
| Trial ID | NCT06800612 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the efficacy and tolerability of various anticancer drug therapies in patients with breast and gynecologic cancers. It will evaluate outcomes such as objective responses, disease-free survival, progression-free survival, overall survival, and side effects by comparing data with existing registry studies. The study includes both retrospective and prospective components, with therapy being administered as per standard clinical practice. Patients enrolled will not undergo additional examinations beyond routine diagnostic investigations.
Who should consider this trial
Good fit: Ideal candidates include patients with histologically confirmed early-stage or metastatic breast cancer or gynecologic cancer who have received treatment since January 2010.
Not a fit: Patients who have not been diagnosed with breast or gynecologic cancers or those who have not received treatment since January 2010 may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the effectiveness and safety of anticancer therapies for breast and gynecologic cancers, potentially improving treatment strategies.
How similar studies have performed: Other studies have shown success in evaluating anticancer therapies, indicating that this approach is supported by existing research.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of histologically confirmed breast cancer or gynecological cancer, either early stage or metastatic; * Patients who have received treatment for breast cancer or gynecologic cancer since January 2010; * Any patient currently living and actually contactable must sign an informed consent to the study and processing of personal data. Exclusion Criteria: * no exclusion criteria
Where this trial is running
Bologna
- IRCCS Azienda Ospedaliero-Universitaria di Bologna — Bologna, Italy (Recruiting)
Study contacts
- Principal investigator: Claudio Zamagni, MD — IRCCS Azienda Ospedaliero-Universitaria di Bologna Policlinico di Sant'Orsola
- Study coordinator: Claudio Zamagni, MD
- Email: zamagniclaudio.sper@aosp.bo.it
- Phone: 0512144548
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.